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Abstract
Introduction: Ventilator-associated pneumonia (VAP) is associated with increased medical resource utilization, but few 
randomized studies have been conducted to evaluate the effect of initial antibiotic therapy. To assess medical resource 
utilization in patients with VAP, we conducted a pooled analysis of two prospective, randomized, open-label, 
multicenter, phase III studies, which also showed that doripenem was clinically noninferior to comparators.
Methods: We assessed durations of mechanical ventilation, intensive care unit (ICU) stay, and hospitalization in 
patients with VAP who received at least 1 dose of doripenem or a comparator in the phase III studies. Comparators 
were piperacillin/tazobactam (study 1) and imipenem (study 2). We analyzed between-group differences in medical 
resource utilization endpoints by comparison of Kaplan-Meier curves with generalized Wilcoxon test and in 
microbiologic eradication rates by two-sided Fisher's exact test.
Results: 625 patients with VAP were evaluated and received at least 1 dose of doripenem (n = 312) or a comparator (n 
= 313). Median durations of mechanical ventilation (7 versus 10 days; P = 0.008) and hospitalization (22 versus 26 days; 
P = 0.010) were shorter for doripenem than comparators; corresponding ICU stays were 12 and 13 days (P = 0.065). All-
cause, overall mortality rates were similar (51/312 [16%] versus 47/313 [15%]; P = 0.648). MIC90 values against 
Pseudomonas aeruginosa for doripenem versus imipenem were 4 versus 16 μg/mL in study 2. P. aeruginosa was 
eradicated from 16/24 (67%) doripenem recipients and 10/24 (42%) comparator recipients (P = 0.147). In patients with 
P. aeruginosa at baseline, median durations of mechanical ventilation (7 versus 13 days; P = 0.031) and ICU stay (13 
versus 21 days; P = 0.027) were shorter for doripenem; corresponding hospital stays were 24 and 35 days (P = 0.129).
Conclusions: Doripenem was associated with lower medical resource utilization than comparators. Differences in 
antipseudomonal activity may have contributed to these findings.
Trial registration: ClinicalTrials.gov number NCT00211003 (study 1) and NCT00211016 (study 2).
Introduction
Ventilator-associated pneumonia (VAP) imposes a bur-
den on medical resources, with attributable hospital costs
ranging from $10,000 to $12,000 per episode [1-3].
Length of stay (LOS) is an important component of hos-
pital costs. VAP adds five days to the duration of mechan-
ical ventilation [1], four to six days to LOS in the ICU
[2,4], and seven days to overall duration of hospitalization
[1]. LOS is even longer in patients with VAP due to
microorganisms that are more virulent, such as
Pseudomonas aeruginosa [4-6], or that are resistant to
imipenem [7] or multiple drugs [8,9].
Appropriate initial antibiotic therapy is vital because
delayed treatment is associated with increased risk of
mortality [4,10-15]. The choice of therapy depends on the
presence of risk factors for multidrug-resistant pathogens
and time of VAP onset. Patients with risk factors or late-
onset VAP are at increased risk of infection due to P.
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aeruginosa  and are therefore candidates for an antip-
seudomonal carbapenem [16].
Doripenem is a broad-spectrum carbapenem with
activity against P. aeruginosa [17]. In phase III studies,
doripenem was clinically noninferior compared with pip-
eracillin/tazobactam in patients with nosocomial pneu-
monia (study 1) [18] and with imipenem in patients with
VAP (study 2) [19]. Additionally, doripenem was associ-
ated with shorter durations of mechanical ventilation and
hospitalization than was imipenem in study 2; between-
group differences in ICU LOS were not significant [20].
Few randomized studies have been conducted to pro-
spectively evaluate the effect of initial antibiotic therapy
on medical resource utilization, such as duration of
mechanical ventilation, ICU LOS, and hospital LOS. To
compare medical resource utilization for doripenem with
that for comparators, we conducted a pooled analysis of
studies 1 [18] and 2 [19]. Considering the added burden
of  P. aeruginosa on resource utilization [4-6], we also
evaluated between-group differences in microbiologic
outcome and medical resource utilization in patients with
P. aeruginosa at baseline.
Materials and methods
Data for this pooled analysis were obtained from two pro-
spective, randomized, open-label, multicenter, phase III
studies, which were conducted between June 2004 and
October 2006 to evaluate whether doripenem was nonin-
ferior to comparator drugs. Study 1 was conducted at 24
centers in North America, 18 in South America, and 26 in
Europe; study 2 was conducted at 37 centers in North
America, 33 in Western Europe, 11 in Australia, and 3 in
other parts of the world. Study designs have been previ-
ously reported [18-20] and were similar, unless otherwise
indicated. Adults were eligible for study 1 if they had clin-
ical and radiologic criteria for nosocomial pneumonia
and early-onset VAP, defined as less than five days of
mechanical ventilation and a Luna Clinical Pulmonary
Infection Score of 5 or more [21]; the pooled analysis
included only the subset with VAP. Adults were eligible
for study 2 if they had VAP as previously defined. Study
protocols and informed consent forms were reviewed and
approved by an institutional review board or ethics com-
mittee at each study center. All patients or their legally
appointed representatives provided written informed
consent.
Eligible patients were stratified by non-VAP and early
VAP in study 1, early and late VAP in study 2 (onset <5
versus ≥5 days), geographic region, and Acute Physiology
and Chronic Health Evaluation (APACHE) II scores (≤15
versus >15). After stratification, patients were randomly
assigned to receive doripenem 500 mg every eight hours
or a comparator, each intravenously. Doripenem was
infused over one hour in study 1 and over four hours in
study 2. In study 1, the comparator was piperacillin/
tazobactam 4.5 g every six hours infused over 30 minutes;
patients who were clinically improved after at least 72
hours of intravenous therapy could be switched to oral
levofloxacin 750 mg daily. In study 2, the comparator was
imipenem 500 mg every six hours infused over 30 min-
utes or 1000 mg every eight hours infused over one hour.
Both studies allowed adjunctive therapy with vancomycin
for suspected methicillin-resistant Staphylococcus aureus
(MRSA) or an aminoglycoside for suspected P. aerugi-
nosa. All antibiotic dosages were adjusted for renal func-
tion; antibiotic concentrations were not collected.
Endpoints were prospectively defined in the phase III
study protocols. Medical resource utilization, which was
retrospectively analyzed from prospectively collected
data in the pooled analysis, included durations of
mechanical ventilation, ICU stay, and hospitalization.
Duration of mechanical ventilation was defined as stop
date - maximum (start date or randomization date) + 1. If
the stop date was not available, the minimum of the fol-
lowing was used for censoring: death, ICU discharge,
hospital discharge, or late follow-up, which occurred 28
to 35 days after the end of intravenous therapy. Duration
of ICU stay was defined as ICU discharge date - maxi-
mum (ICU admit date or randomization date) + 1. Nine
patients were excluded from ICU analysis because they
had valid ICU admittance dates but no valid ICU dis-
charge dates and had hospital discharge dates (dorip-
enem, 3; comparator, 6). Duration of hospitalization was
defined as (discharge date or death date) - randomization
date + 1. If discharge date was not available, patients were
censored at late follow up. In addition, all-cause overall
mortality and, in patients with P. aeruginosa at baseline,
minimal inhibitory concentrations (MIC), eradication
rate, and resource utilization were evaluated.
Statistical analyses
Medical resource utilization endpoints were analyzed in
all patients who received at least one dose of study drug,
defined as the intent-to-treat (ITT) population, and who
met the clinical definition of VAP (clinical modified ITT)
[19]. Microbiologic endpoints were analyzed in patients
from whom P. aeruginosa alone or with other microor-
g a n i s m s  h a d  b e e n  i s o l a t e d  a t  b a s e l i n e  f r o m  t h e  l o w e r
respiratory tract.
Between-group differences in medical resource utiliza-
tion endpoints were analyzed by comparison of Kaplan-
Meier curves with Gehan's generalization of the Wil-
coxon test [22], whose weighting scheme reduces the rel-
ative contribution of patients with prolonged LOS due to
other (non-VAP) conditions by placing more weight on
early versus later discharges. Between-group differences
in microbiologic eradication rates were analyzed by two-Kollef et al. Critical Care 2010, 14:R84
http://ccforum.com/content/14/3/R84
Page 3 of 10
sided Fisher's exact test and in LOS by generalized Wil-
coxon test.
Effect of covariates on outcome variables, as well as
treatment effect after controlling for important covari-
ates, was examined with Cox proportional hazards
regression model. Variables were selected by the best-
subsets model-selection method, where the smallest
model with statistically significant variables was included;
the P value for inclusion in the model was less than 0.05.
In addition, baseline microbiology of P. aeruginosa or
MRSA was included as a clinically important variable.
Assumption of proportional hazards was tested in each
case by examining the effect-by-time interaction effect
jointly for all covariates, and individually for each covari-
ate entered into the model. The proportional hazards
assumption was validated for each model.
Statistical Analysis Software version 9.1.3 (SAS Insti-
tute, Inc., Cary, NC, USA) was used for statistical analy-
ses. P values less than 0.05 were considered statistically
significant.
Results
Of 979 patients randomized to receive doripenem (n =
489) or a comparator (n = 490) in studies 1 and 2 (Figure
1), 354 were excluded from the pooled analysis because
they did not receive the study drug (n = 10) or did not
meet clinical diagnostic criteria for VAP (n = 344). Most
of these exclusions occurred in patients enrolled in study
1 who had nosocomial pneumonia but not VAP. In the
remaining 625 patients, none of the tests for between-
group differences in demographics, clinical characteris-
tics, and adjunctive medication use yielded statistically
significant results (Table 1). All remaining patients were
included in the pooled analysis except four who received
comparators and did not have valid medical resource uti-
lization data.
Durations of mechanical ventilation and hospitalization
were shorter among patients treated with doripenem
than among those treated with a comparator; between-
group differences in ICU stay were not statistically signif-
icant (Table 2). For example, median duration of mechan-
ical ventilation was 7 days for doripenem and 10 days for
comparators; the P  value for the Kaplan-Meier curve
comparison was 0.008 (Figure 2). Similar trends were
seen for the subset of patients who either survived or died
seven or more days after stopping mechanical ventilation.
All-cause, overall mortality occurred in 51 (16%) of 312
Figure 1 Patient disposition. cMITT, clinically modified ITT (population); ITT, intent-to-treat (population); VAP, ventilator-associated pneumonia.
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Table 1: Demographics, clinical characteristics, and drug use for study patientsa
Characteristic Number of patients (%), unless otherwise stated
Study 1 Study 2 Pooledb
Doripenem (n = 63) Pip/Tazo (n = 61) Doripenem (n = 249) Imipenem (n = 252) Doripenem (n = 312) Comparator (n = 313)
Mean age, years (SD) 50.8 (20.1) 54.0 (20.4) 51.4 (19.8) 51.7 (18.7) 51.3 (19.8) 52.2 (19.0)
Men 42 (66.7) 46 (75.4) 195 (78.3) 192 (76.2) 237 (76.0) 238 (76.0)
APACHE II ≤15 35 (55.6) 32 (52.5) 117 (47.0) 120 (47.6) 152 (48.7) 152 (48.6)
Race
White 39 (61.9) 40 (65.6) 217 (87.1) 209 (82.9) 256 (82.1) 249 (79.6)
Black 7 (11.1) 3 (4.9) 22 (8.8) 28 (11.1) 29 (9.3) 31 (9.9)
Hispanic 16 (25.4) 17 (27.9) 9 (3.6) 10 (4.0) 25 (8.0) 27 (8.6)
Other 1 (1.6) 1 (1.6) 1 (0.4) 5 (2.0) 2 (0.6) 6 (1.9)
VAP onset
Early (<5 days) 63 (100.0) 61 (100.0) 98 (39.4) 97 (38.5) 161 (51.6) 158 (50.5)
Late (≥5 days) 0 (0.0) 0 (0.0) 151 (60.6) 155 (61.5) 151 (48.4) 155 (49.5)
Adjunctive drug usage
Amikacin 52 (82.5) 51 (83.6) 28 (11.2) 40 (15.9) 80 (25.6) 91 (29.1)
Vancomycin 18 (28.6) 13 (21.3) 70 (28.1) 74 (29.4) 88 (28.2) 87 (27.8)
Oral levofloxacin 9 (14.3) 7 (11.5) Not applicable 9 (2.9) 7 (2.2)
Baseline microbiologyc
Pseudomonas 
aeruginosa
6 (9.5) 11 (18.0) 30 (12.0) 26 (10.3) 36 (11.5) 37 (11.8)
MRSA 6 (9.5) 3 (4.9) 14 (5.6) 16 (6.3) 20 (6.4) 19 (6.1)
Surgery 45 (71.4) 41 (67.2) 193 (77.5) 194 (77.0) 238 (76.3) 235 (75.1)
a Patients who received one dose or more of study drug and met clinical diagnostic criteria for VAP.
b P > 0.05, doripenem versus comparator.
c Percentages were based on all patients, including some patients with unknown baseline microbiology.
APACHE, Acute Physiology and Chronic Health Evaluation; MRSA, methicillin-resistant Staphylococcus aureus; Pip/Tazo, piperacillin/tazobactam; SD, standard deviation; VAP, ventilator associated 
pneumonia.Kollef et al. Critical Care 2010, 14:R84
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patients in the doripenem group and in 47 (15%) of 313
patients in the comparator group (P = 0.648).
In the Cox proportional hazards model, patients in the
doripenem group were 1.3 times more likely to be
weaned from mechanical ventilation (P = 0.005) or dis-
charged from the hospital (P = 0.004) than those in the
comparator group (Table 3). Hazard ratios for treatment
with doripenem versus comparators corresponding to
risk of stopping mechanical ventilation (P = 0.006) and
hospital discharge (P  = 0.004) remained significantly
above one after adjusting for other significant covariates,
such as presence of P. aeruginosa. The hazard ratio corre-
sponding to risk of ICU discharge was not significantly
different from one before (P = 0.079) or after (P = 0.122)
adjusting for significant covariates.
In the subset of patients with P. aeruginosa at baseline,
this pathogen was eradicated or presumed eradicated
from 16 (67%) of 24 patients in the doripenem group and
from 10 (42%) of 24 patients in the comparator group (P =
0.147; Table 4). In study 1, MIC50 values were 0.5 μg/mL
for doripenem and 4.0 μg/mL for piperacillin/tazobac-
tam, and corresponding MIC90 values were 1 and 128 μg/
Figure 2 Kaplan-Meier curve of duration of mechanical ventilation. Asterisks represent censored observations.Kollef et al. Critical Care 2010, 14:R84
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Page 6 of 10
mL (Figure 3). In study 2, MIC50 values were 0.25 μg/mL
for doripenem and 2.0 μg/mL for imipenem, and corre-
sponding MIC90 values were 4 and 16 μg/mL. Median
durations of mechanical ventilation (7 versus 13 days;
generalized Wilcoxon P = 0.031) and ICU stay (13 versus
21 days; P = 0.027) were shorter for doripenem; between-
group differences in hospital stay were not statistically
significant.
Discussion
The results of this pooled analysis of two phase III studies
indicated that initial use of doripenem in patients with
VAP was associated with shorter durations of mechanical
ventilation and hospitalization than was use of compara-
tor antibiotics. Between-group differences in hospital
LOS remained significant in the subset of patients who
s u r v i v e d  o r  d i e d  s e v e n  o r  m o r e  d a y s  a f t e r  s t o p p i n g
mechanical ventilation, suggesting that the difference was
not due to an imbalance in mortality. Treatment group
was associated with durations of mechanical ventilation
and hospitalization after adjusting for other significant
covariates in the regression analysis. Median duration of
mechanical ventilation in the comparator group (10 days)
was generally consistent with that in previous cohort
studies of patients with VAP (10 to 14 days) [1,23]. Simi-
larly, duration of hospitalization (26 days) was within the
range in previous studies (15 to 38 days) [1,3,23].
To further elucidate our findings, we evaluated patients
with P. aeruginosa at baseline. Microbiologic eradication
rates were 67% for doripenem and 42% for comparators;
however, the between-group difference was not statisti-
cally significant, presumably because of the limited num-
ber of patients in this subset. We also found that
doripenem had lower MIC values than did imipenem.
Comparison of MIC values among different antibiotic
classes are not an indication of clinical efficacy; however,
free time above MIC in serum (fT>MIC) can be used as a
surrogate for comparison. This pharmacokinetic/phar-
macodynamic index correlates with clinical efficacy and
bactericidal activity and is used to determine antibiotic
dosage regimens [24,25]. Pharmacodynamic modeling
reveals that the doripenem dosages would have a 99 to
100% probability of achieving a target fT>MIC for the
MIC90 values in study 1 (1 μg/mL) and study 2 (4 μg/mL)
[26]. In contrast, the piperacillin/tazobactam dosage
would have a very low probability of achieving a target
fT>MIC for the MIC90 (128 μg/mL) in study 1 [27].
Finally, we found significant between-group differences
in medical resource utilization favoring doripenem in
patients with P. aeruginosa at baseline for duration of
mechanical ventilation and also for ICU LOS, whereas
that for hospital LOS was not significant. As expected,
each measure of medical resource utilization was greater
for patients in the comparator group with P. aeruginosa at
baseline than for those without P. aeruginosa. For exam-
ple, median duration of mechanical ventilation was 10
days for all patients with VAP and 13 days for the subset
with P. aeruginosa at baseline. Vidaur and colleagues [5]
reported that, when patients were treated with inappro-
priate antibiotics, clinical resolution occurred more
slowly if VAP was due to P. aeruginosa than due to other
pathogens. Interestingly, each measure of medical
resource utilization was nearly identical for patients in
the doripenem group, regardless of whether P. aeruginosa
Table 2: Medical resource utilization in VAP patients who received at least one dose of study drug
Type of resource Median duration in days (95% CI), unless otherwise stated P Value
Doripenem Comparator
All patients (n = 312)a (n = 309)a
Mechanical ventilation 7 (7-8) 10 (8-11) 0.008
ICU 12 (11-13) 13 (12-16) 0.065
Hospital 22 (20-25) 26 (23-29) 0.010
Patients who survived or died ≥7 days after stopping 
mechanical ventilation
(n = 282)a (n = 270)a
Mechanical ventilation 7 (7-8) 9 (7-11) 0.053
ICU 13 (11-14) 14 (12-16) 0.162
Hospital 23 (21-27) 28 (26-32) 0.004
Mortality, n/N (%) 51/312 (16.3) 47/313 (15.0) 0.648
a Number of patients assessed for duration of hospitalization. Some patients had missing data for durations of mechanical ventilation and ICU 
stay.
CI, confidence interval; VAP, ventilator-associated pneumonia.Kollef et al. Critical Care 2010, 14:R84
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Table 3: Cox proportional hazards regression for medical resource utilization
Parameter Hazard ratioa 95% Confidence interval P value
Duration of mechanical ventilation
Unadjusted results
Treatment (doripenem) 1.29 1.08-1.53 0.005
Adjusted results
Treatment (doripenem) 1.28 1.07-1.52 0.006
Baseline MRSA (presence) 0.72 0.50-1.04 0.079
Baseline Pseudomonas aeruginosa (presence) 0.79 0.60-1.04 0.087
Baseline APACHE II scoreb (≤20 versus >20) 0.77 0.61-0.95 0.017
ICU LOS
Unadjusted results
Treatment (doripenem) 1.16 0.98-1.37 0.079
Adjusted results
Treatment (doripenem) 1.14 0.97-1.35 0.122
Baseline P. aeruginosa (presence) 0.73 0.56-0.95 0.018
Region (North America) 1.22 1.04-1.45 0.018
Baseline APACHE II score 0.97 0.96-0.99 0.003
Total hospital LOS
Unadjusted results
Treatment (doripenem) 1.32 1.09-1.58 0.004
Adjusted results
Treatment (doripenem) 1.31 1.09-1.58 0.004
VAP onset (early) 1.30 1.08-1.57 0.005
Baseline P. aeruginosa (presence) 0.83 0.62-1.11 0.212
Region (North America) 1.51 1.25-1.82 <0.001
a A hazard ratio significantly greater than 1 indicated that discharge was more likely to occur.
b APACHE II score was dichotomous (not continuous as in previous models) to satisfy the proportional hazards assumption.
APACHE II, Acute Physiology and Chronic Health Evaluation II; LOS, length of stay; MRSA, methicillin-resistant Staphylococcus aureus; VAP, 
ventilator-associated pneumonia.
was present. Therefore, these findings suggest that dorip-
enem may have prevented the increased medical resource
utilization associated with P. aeruginosa at baseline
reported in other studies [4-6] because of activity against
key pathogens. Consideration of the influence of appro-
priateness of empiric therapy against subsequently identi-
fied pathogens was beyond the scope of this economic
analysis and merits further evaluation.
The lack of statistically significant between-group dif-
ference in one of three measures of medical resource uti-
lization is puzzling, given the relation between the
outcome measures. In the subset with P. aeruginosa at
baseline, the absolute difference in hospital LOS was nine
days. The absolute difference in ICU stay was only one
day in all patients and is more difficult to explain. During
acute critical illness requiring ICU stay of more than 48
hours, health-related quality of life (HRQOL) declines
rapidly. After patients are discharged from the ICU,
HRQOL begins to recover and reaches near pre-ICU
admission levels by the time of hospital discharge [28].
Therefore, an intervention with a more rapid effect on
VAP may allow patients to recover more quickly on the
ward and to be discharged from the hospital more
quickly. This hypothesis requires further evaluation with
repeated assessment of HRQOL throughout hospitaliza-
tion and after discharge.
Our findings address a gap in the literature regarding
the effect of initial antibiotic therapy on medical resource
utilization in patients with VAP. The larger, combined
sample provided a sufficient number of patients with P.
aeruginosa at baseline to show a statistically significant
difference between those who received doripenem and
those who received a comparator, which was not detected
in a previous study containing only a portion of the com-Kollef et al. Critical Care 2010, 14:R84
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bined sample [20]. These between-group differences may
have clinical implications. Specifically, shortening LOS
may decrease the cost of hospitalization as demonstrated
in a recent economic analysis of studies 1 and 2 [29].
Using discrete event simulation, Kongnakorn and col-
leagues [29] estimated that use of doripenem instead of
imipenem for treatment of VAP would yield a per-patient
saving of approximately $12,260 primarily due to reduced
durations of mechanical ventilation, ICU stay, and hospi-
talization. In addition, shortening LOS may decrease the
r i s k  o f  n o s o c o m i a l  c o m p l i c a t i o n s,  s u c h  a s  e x p o s u r e  t o
resistant microorganisms and recurrent VAP. Carmeli
and colleagues [30] were among the first to report the
economic burden of antibiotic resistance in P. aeruginosa.
Emergence of resistance during hospitalization was asso-
ciated with longer hospital LOS and increased risk of sec-
ondary bacteremia in their cohort study [30].
Our study had several limitations. First, this was a post
hoc analysis, although data were collected prospectively
and analysis of medical resource utilization was intended
for the individual studies. Second, both study designs
were open label, which may have affected medical
resource utilization; however, bias should be minimal
because the decision of whether to discharge patients or
discontinue mechanical ventilation was likely to be based
on overall health and predefined institutional procedures
rather than treatment assignment, and the number of
investigators was large.
Third, the studies were not identical, but they were sim-
ilar except for the following. Study 1 excluded patients
Figure 3 Distribution of minimal inhibitory concentrations for Pseudomonas aeruginosa. The number of isolates was 5 for doripenem and 11 
for piperacillin/tazobactam in study 1, and 28 for doripenem and 25 for imipenem in study 2.
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Table 4: Microbiologic outcome and resource utilization in patients with ventilator-associated pneumonia due to 
Pseudomonas aeruginosa
Outcome Doripenem Comparator P value
Eradication rate, n/N (%)a 16/24 (66.7) 10/24 (41.7) 0.147b
Median duration, days (95% CI) (n = 36) (n = 37)
Mechanical ventilation 7 (5-9) 13 (8-16) 0.031c
ICU 13 (9-19) 21 (14-30) 0.027c
Hospital 24 (20-32) 35 (28-N/A) 0.129c
a Eradication rate defined as microbiologic eradication or presumed eradication. Twenty-five patients excluded from evaluation of 
eradication rates for doripenem (n = 12) and comparator (n = 13) because of lack of data.
b Two-sided Fisher's exact test.
c Generalized Wilcoxon test.
CI, confidence interval; N/A, not available.Kollef et al. Critical Care 2010, 14:R84
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with late-onset VAP; study 2 included patients with early-
and late-onset VAP. Study 1 (n = 123) had fewer patients
than study 2 (n = 501). Doripenem was infused over one
hour in study 1 and four hours in study 2. Comparators
were piperacillin/tazobactam in study 1 and imipenem in
study 2. Fourth, excluding patients without VAP from
study 1 may have partially offset the benefits of random-
ization in that study; however, all patients in the clinically
m o d i f i e d  I T T  p o p u l a t i o n  w e r e  i n c l u d e d  f r o m  s t u d y  2 ,
which was larger than study 1.
Fifth, not all LOS was attributable to VAP. Patients
could have been admitted for other reasons and subse-
quently acquired VAP. Furthermore, patients with VAP
are critically ill and have other comorbidities that con-
tribute to LOS. Additionally, we did not capture data
needed to eliminate the possibility that social circum-
stances or other factors led to earlier discharge of patients
who received doripenem, but randomization should have
offset any between-group differences. Also, we used a sta-
tistical test that places more weight on early discharges
than on late discharges and did not consider ICU read-
missions. Sixth, the analyses do not prove a cause-and-
effect relation between doripenem and shorter LOS, but
statistical models were used to address covariates likely to
influence treatment and outcome.
Conclusions
This pooled analysis of two prospectively randomized
phase III studies suggests that doripenem use for the
treatment of VAP was associated with shorter durations
of mechanical ventilation and hospitalization. Differences
in antipseudomonal activity may have contributed to
these findings. Our economic findings, combined with
previous clinical findings, suggest that doripenem may be
considered an alternative for empirical treatment of VAP,
especially when P. aeruginosa is suspected or prevalent.
More studies are needed to confirm these preliminary
findings and to define the clinical and economic value of
doripenem in patients with VAP.
Key messages
• Initial doripenem use in patients with VAP was
associated with statistically significant shorter dura-
tions of mechanical ventilation (median, 7 versus 10
days) and hospitalization (median, 22 versus 26 days)
than was use of comparator antibiotics (piperacillin/
tazobactam or imipenem) in a pooled analysis of two
phase III studies.
• Initial doripenem use was also associated with sta-
tistically significant shorter durations of mechanical
ventilation (median, 7 versus 13 days) and ICU stay
(median, 13 versus 21 days) in the subset with P.
aeruginosa at baseline.
• The economic findings from this paper, combined
with previous clinical findings, suggest that dorip-
enem may be considered an alternative for empirical
treatment of VAP, especially when P. aeruginosa is
suspected or prevalent.
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